Saturday 17 October 2026
Export RGC’s income statement to Excel — free account
Regencell Bioscience Holdings Limited
RGC Healthcare Drug Manufacturers Specialty & Generic
Dividend growth for three consecutive years.
9.59
0.07
+0.74%
Follow RGC
| Dec '25 | Jun '25 | Jun '24 | Jun '23 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | 0.00% | 0.00% | (336.98%) |
+7 more TTM periods Free account |
|
| 0.00% | 0.00% | 0.00% | (207.77%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 0.00% | 0.00% | (112.86%) | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(14.67) | (18.31) | (15.81) | (12.19) | |
Capital Expenditures |
— | (0.97) | (0.81) | (0.82) | |
| Other line items | |||||
Cash ROIC |
(410.18%) | (187.68%) | (97.72%) | (51.77%) | |
Tax Rate |
— | — | — | 0.00 | |
Research and Development Expense of Revenue |
— | — | — | 0.00% | |
Selling, General and Administrative Expense of Revenue |
— | — | — | 0.00% | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.84 | |
Depreciation/Fixed assets |
0.00 | 0.77 | 0.84 | 0.53 | |
Capex/Depreciation |
— | (1.17) | (1.05) | (1.70) | |
Revenue per Share |
— | — | — | 0.00 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 9 Oct 2026